Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8 + T-cell infiltration in hepatocellular carcinoma.

Fei SongBo HuXiao-Liang LiangJian-Wen ChengCheng-Gui WangPeng-Xiang WangTian-Lun WangPeng-Ju TangHai-Xiang SunWei GuoJian ZhouJia FanZhong ChenXin-Rong Yang

Published in: Clinical and translational medicine (2024)

Synergistic effects of anlotinib and anti-PD-1 immunotherapy demonstrated in HCC preclinical models. Anlotinib inhibits TFRC expression via the VEGFR2/AKT/HIF-1α pathway. CXCL14 upregulation via TFRC suppression boosts CD8+ T-cell recruitment. TFRC emerges as a potential biomarker for evaluating prognosis and predicting response to anti-PD-1-based therapies in advanced HCC patients.

Keyphrases

poor prognosis
end stage renal disease
cell proliferation
signaling pathway
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
binding protein
stem cells
drug delivery
cancer therapy
vascular endothelial growth factor